Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
" In view of : - the efficacy and safety data versus placebo, - the absence of direct comparative data versus other anti-ANF agents, particularly infliximab, the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies." |
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
snX72pwHwrTnxhyy
